The Evolving Therapeutic Landscape for HER2-Positive Early-Stage Breast Cancer

Download this slideset from Lee Schwartzberg, MD, FACP to review key data on optimal treatment for HER2-positive early breast cancer, including neoadjuvant and adjuvant therapy.
Lee Schwartzberg, MD, FACP
Format: Microsoft PowerPoint (.ppt)
File Size: 1,005 KB
Released: August 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Puma Biotechnology

Related Content

Enter details about your patient with HER2+ MBC into this online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Aditya Bardia, MD, MPH Sara Hurvitz, MD, FACP Komal Jhaveri, MD Heather McArthur, MD, MPH Sara Tolaney, MD, MPH Released: November 23, 2022

Expert commentary with Dr Charles Geyer on the essential need for BRCA testing in early breast cancer to guide adjuvant olaparib decisions, from Clinical Care Options (CCO) and ProCE

Charles E. Geyer, Jr., MD Released: November 17, 2022

A patient describes her journey with early breast cancer and the critical role of good communication between patients and their healthcare providers in this short video by Clinical Care Options (CCO)

person default Zoe Lanham Released: November 16, 2022

Downloadable slides on multidisciplinary approaches to managing high-risk, HR-positive/HER2-negative early breast cancer, from Clinical Care Options, (CCO)

Erika P. Hamilton, MD
Program Director
Joyce O'Shaughnessy, MD
Program Director
Released: November 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings